EDAP - Earnings announcements

, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for c

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures69% Full-Year YoY Growth in Focal One System Placements28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure GrowthDemand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - E

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before market open on Wednesday, March 25, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below f

EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes167% YoY Growth in Focal One System Placements15% YoY Growth in U.S. Focal One HIFU ProceduresCompany to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025. "Our record-breaking third-quarter revenue performance reflects the continued strong demand for our leading Focal One Robotic HIFU platform, with system placements increasing 167% year o

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the markets open on Thursday, November 6th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference ca

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

+140% Focal One® Net Placement Growth Year over Year+76.8% HIFU Revenue Growth Year over Year 36 million Euro Credit Facility Letter of Intent Executed with European Investment Bank (EIB) to further accelerate HIFU Growth and Strategic Expansion Company raises 2025 HIFU Year over Year Revenue Growth Guidance range to 26% to 34%, up from the prior range of 16% to 25%  Company to Host Conference Call and Webcast Today, August 28th, at 8:30 a.m. EDT  AUSTIN, Texas, August 28, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2025. "We experienced our strongest second quarter

Company to host conference call and webcast on Thursday, August 28th at 8:30am EDT AUSTIN, Texas, August 7, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the markets open on Thursday, August 28th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:           

          Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World's First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the first quarter of 2025. "Demand for Focal One remai

Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

            Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023U.S. Focal One HIFU procedures grew 51% on a year-over-year basis in 2024Focal One receives CE Mark for the treatment of deep infiltrating endometriosisRecent landmark HIFI study publication demonstrates positive outcomes with Focal One® Robotic HIFU versus surgery in the management of prostate cancerFirst patients treated in Phase I/II study evaluating Focal One Robotic HIFU for the treatment of Benign Prostatic Hyperplasia (BPH)Company to host conference call and webcast today, March 27th, at 8:30 a.m.

Company to host conference call and webcast on Thursday, March 27th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Da

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors ("Board"). "We are excited to welcome Fran to the Senti Bio Board of Directors," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "Fran's deep expertise in the life sciences industry—spanning finance, strategic planning, operations, and transactions—wi

         Reported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of EUR 4.5 million (USD 4.9 million), increasing 48.2% over Q3 202334% year-over-year growth in U.S. Focal One HIFU procedures CMS increases Medicare Hospital Outpatient Focal One HIFU procedure payment by 5.4% for 2025Announced AI collaboration with Avenda Health for Focal One Robotic HIFUCompany to host conference call and webcast today, November 7th, at 8:30 a.m. EDT LYON, France, November 7, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the thi

Company to host conference call and webcast on Thursday, November 7th at 8:30am EDT LYON, France, October 24, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2024, before the markets open on Thursday, November 7th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:     

        Record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% over Q2 2023Record first half 2024 total worldwide revenue of EUR 30.7 million (USD 33.1 million) increased 5.6% over first half 2023Strong Q2 2024 U.S. Focal One® HIFU procedure growth of +63% year-over-yearCompany to host conference call and webcast today, August 28th, at 8:30 a.m. EDT LYON, France, August 28, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2024. "We continue to see growing demand for our proprietary and leading Focal One robot

Company to host conference call and webcast on Wednesday, August 28th at 8:30am EDT LYON, France, August 7, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2024, before the markets open on Wednesday, August 28th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:Wednesday, A

         Strong Q1 2024 U.S. Focal One® HIFU procedure growth of +92% year-over-year Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023Q1 2024 total revenue of EUR 14.9 million ($16.1 million USD) increased 0.8% over Q1 2023Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT LYON, France, May 16, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the first quarter of 2024. "We are off to a strong start in 2024 driven by seven Focal One system placements in the quarter of 2024 and strong year over year procedure growth, reflecting the incre

Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT LYON, France, May 2, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date: Thursday, May 16th  

Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022Record full-year 2023 total revenue of EUR 60.4 million ($65.4 million USD) increased 9.6% over full-year 2022Record full-year 2023 HIFU revenue of EUR 20.6 million ($22.3 million USD), an increase of 31.7% over full-year 2022Strong Q4 2023 U.S. Focal One® HIFU procedure growth of +136% year-over-year Company to host conference call and webcast today, March 27th, at 8:30 a.m. EDT LYON, France, March 27, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, re

Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details:

- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year - - Record nine months HIFU revenues reflecting growing demand - - Two additional Focal One systems already placed in the fourth quarter - - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology - - Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT - LYON, France, November 9, 2023 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023. "We continue to see stronger

Company to host conference call and webcast on Thursday, November 9th at 8:30am EDT LYON, France, October 26, 2023 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th, 2023, before the markets open on Thursday, November 9th, 2023. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary. The call will be held at 8:30am EDT on Thursday, November 9th, 2023. Please refer to the information bel

- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD 31.5 million), respectively - - Total HIFU Q2 2023 year-over-year revenue growth of 63.6% - - Strong Q2 2023 year-over-year U.S. Focal One® HIFU procedure growth of 85% - - Received reimbursement approval in Switzerland for use of HIFU in the treatment of prostate cancer - - More than half of patients now enrolled in Phase 3 study evaluating Focal One HIFU in endometriosis - - Appointment of Ryan Rhodes to Board of Directors - - Company to host conference call and webcast today, Thursday, August 24th at 8:30 am EDT - LYON, France, August 24, 20

- Company to host conference call and webcast on Thursday, August 24th at 8:30 am EDT - LYON, France, August 10, 2023 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30th, 2023, before the markets open on Thursday, August 24th, 2023. An accompanying conference call and webcast will be hosted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary. The call will be held at 8:30am EDT on Thursday, August 24th, 2023. Please refer to the information below for conference call dial-

- Record first quarter revenue - - Positive results from two studies reconfirm safety and efficacy of Focal One - - Company to host conference call and webcast today, Wednesday, May 17that 8:30 am EDT - LYON, France, May 17, 2023 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter ended March 31, 2023. "After achieving record results in the fourth quarter of 2022, we continued to see growing demand through the first quarter of 2023, with our strongest Q1 revenue performance on record," said Ryan Rhodes, Chief Executive Officer of EDAP. "We placed seven Focal One units, including six equipment

- Company to host conference call and webcast on Wednesday, May 17that 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31st, 2023 before the markets open on Wednesday, May 17th, 2023. An accompanying conference call and webcast will be hosted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer, and Ken Mobeck, Chief Financial Officer of the U.S. Subsidiary. The call will be held at 8:30 am EDT on Wednesday, May 17th, 2023. Please refer to the information below for conferenc

Record full-year 2022 total revenue of EUR 55.1 million ($58.0 million) increased 25.1% over full-year 2021Full-year HIFU revenue was EUR 15.6 million (USD 16.4 million), an increase of 57.7% as compared to EUR 9.9 million (USD 11.7 million) for the full-year 2021Record Q4 2022 total revenue of EUR 15.7 million ($16.2 million) versus EUR 14.0 million ($15.9 million) for Q4 2021Ended the year with a strong cash position of EUR 63.1 million ($67.5 million) as of December 31, 2022Ryan Rhodes to succeed Marc Oczachowski as Chief Executive Officer of the Company, effective May 1, 2023Company to host conference call and webcast today, March 30th, at 8:30 a.m. ET LYON, France, March 30, 2023 -

LYON, France, March 9, 2023 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30th, 2023. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, March 30th, 2023. Please refer to the information below for the conference call dial-in information and webcast registration.

Generated Q3 2022 total revenue of approximately EUR 12.2 million (USD 12.3 million), an increase of 29.7 % as compared to EUR 9.4 million (USD 11.1 million) for Q3 2021; nine-month year-to-date revenue increased 30.9% compared to the same period in 2021Generated HIFU sales of EUR $3.5 million (USD 3.5 million), representing growth of 81% over EUR 1.9 million (USD 2.3 million) for Q3 2021Reimbursement increase finalized: U.S. Centers for Medicare and Medicaid Services (CMS), in its final Outpatient Prospective Payment System (OPPS) rule for CY23, increased reimbursement for HIFU prostate ablation from APC Level 5 to Level 6 which increases hospital reimbursement by more than 90%Exited the qu

Company to host conference call and webcast on Thursday, November 17th at 8:30 am EDT LYON, France, November 2, 2022 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th after the markets close on Wednesday, November 16th, 2022. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, November 17th, 2022. Please refer to the information below for conference call d

Final rule significantly raises Medicare reimbursement to U.S. hospitals performing a Focal One HIFU prostate ablation procedure LYON, France, November 1, 2022 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic therapeutic ultrasound, today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has released its final outpatient prospective payment system (OPPS) reimbursement rule for calendar year 2023 (CY23), which becomes effective on January 1st. For a hospital performing a Focal One HIFU prostate ablation on an outpatient basis, the final rule increases the reimbursement level to an Ambulatory Payment Classification (APC) level 6, as compared t

Announced Focal One® HIFU reimbursement raised to urology APC Level 6 under CMS Outpatient Prospective Payment System (OPPS) proposed rule for CY23Second quarter 2022 total revenue of approximately EUR 14.2 million (USD 15.0 million), an increase of 36.7% as compared to EUR 10.4 million (USD 12.4 million) for the second quarter 202179% growth in HIFU revenues for the first half of 2022 compared to same period in 2021Strong cash position of $48.5 million as of June 30, 2022Company to host Focal One Expert User Panel event in New York City on Thursday, September 29Second quarter conference call and webcast scheduled for tomorrow, Thursday, August 25, at 8:30 am ET LYON, France, August 24, 20

Company to host conference call and webcast on Thursday, August 25th at 8:30 am EDT LYON, France, August 3, 2022 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30th after the markets close on Wednesday, August 24th, 2022. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, August 25th, 2022. Please refer to the information below for conference call dial-in

First quarter 2022 revenue of approximately EUR 13.0 million (USD 14.5 million), an increase of 26% as compared to EUR 10.3 million (USD 12.4 million) for the first quarter 2021Four Focal One units sold in Q1 2022 versus zero in Q1 2021Strong cash position of $51.6 million as of March 31, 2022Company to host a conference call tomorrow, Wednesday, May 18, at 8:30 am ET LYON, France, May 17, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), a global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter 2022. Marc Oczachowski, EDAP's Chairman and Chief Executive Officer, said: "As we announced in our business update press release jus

Company to host conference call and webcast on, Wednesday, May 18th at 8:30 am EDT LYON, France, May 10, 2022 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31st, 2022 after the markets close on Tuesday, May 17th, 2022. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, May 18th, 2022. Please refer to the information below for conference call dial-in infor

Full year revenue of approximately EUR 44.1 million (USD 51.9 million) as compared to EUR 41.7 million (USD 47.8 million) for the full year 2020Full year US HIFU treatment volumes increased 65% over full year 2020; Strong cash position of EUR 47.2M€ (USD 53.4M) as of December 31, 2021Company to host a conference call tomorrow, Thursday, March 31, at 8:30 am ET LYON, France, March 30, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), a global leader in robotic energy-based therapies, announced today unaudited financial results for the fourth quarter and full year 2021. Marc Oczachowski, EDAP's Chairman and Chief Executive Officer, said: "We finished 2021 on a positive note, having rep

Company to host conference call and webcast on Thursday, March 31, at 8:30 am ET LYON, France, March 21, 2022 - EDAP TMS SA (NASDAQ:EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter ended December 31, 2021 after the markets close on Wednesday, March 30, 2022. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, March 31, 2022. Please refer to the information below for conference call dial-in inf

Company announces several key U.S. Focal One installations during Q4 LYON, France, January 5, 2022 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today provided an update on recent Focal One placements and the initiation of treatments at select new customer sites in the US. During the company's third quarter 2021 conference call in November, EDAP announced that it had sold a Focal One device to the University of California at San Diego (UCSD) during the fourth quarter. The sale to UCSD is now the third Focal One placement into the prestigious UC healthcare system, following previously announced sales to UC San Francisco and UC I

Year-to-date revenue of approximately EUR 30.1 million (USD 35.9 million) increased 14.4% year-over-year Q3 revenue of EUR 9.4 million (USD 11.1 million), flat with Q3 2020, reflecting lingering impact of COVID-19 on capital equipment sales Year-to-date US HIFU treatment volumes increased 58% over the comparable period in 2020; strong leading indicator of Focal One adoption by urologistsStrong cash position of EUR 45.4 million (USD 52.6 million)Company to host a conference call tomorrow, Thursday, November 18, at 8:30 am ET LYON, France, November 17, 2021 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), a global leader in robotic energy-based therapies, announced today unaudited financial re

Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET LYON, France, November 10, 2021 - EDAP TMS SA (NASDAQ:EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2021 after the markets close on Wednesday, November 17, 2021. An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, Chief Executive Officer of EDAP U.S.A., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, November 18, 2021. Please refer to the information below

Total revenue for the first half 2021 of EUR 20.7 million (USD $24.8 million) increased 22.5% over the same period of the prior year Net income was EUR 0.4 million (USD 0.4 million), or EUR 0.01 per diluted share, for the first half of 2021Cash balance of EUR 45 million (USD $53.3 million) as of June 30, 2021Second quarter U.S. HIFU treatment volumes increased 79% over the comparable period in 2020; strong leading indicator of Focal One adoptionCMS Advisory Panel on Hospital Outpatient Payment (HOP panel), at its summer meeting, unanimously recommended increasing reimbursement for HIFU prostate ablation to APC Level 6 in 2022 from Level 5 currentlyCompany to host a conference call tomorrow,

Total company second quarter 2021 revenue of approximately EUR 10.4 million (USD $12.4 million) increased 11.8% year-over-year; first half 2021 total company revenue of EUR 20.7 million (USD $24.8 million) increased 22.5%During the second quarter, U.S. HIFU treatment volumes increased 79% over the comparable period in 2020Ended the second quarter 2021 with cash and cash equivalents of EUR 45 million (USD $53.3 million)Announced hiring of veteran robotic medical device executive Ryan Rhodes as Chief Executive Officer of the company's U.S. subsidiary, EDAP Technomed Inc.Company to report full second quarter financial and operating results on Wednesday, August 25, and host a conference call on